Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
Launched by GALDERMA R&D · Jan 8, 2020
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Male or female at least 18 years of age.
- Exclusion Criteria:
- • Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.
- • Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than the investigational product).
- • Female who is pregnant, breast feeding, or intends to conceive a child during the study.
- • Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chestnut Hill, Massachusetts, United States
Fremont, California, United States
Boca Raton, Florida, United States
Aventura, Florida, United States
Birmingham, Alabama, United States
Dallas, Texas, United States
Coral Gables, Florida, United States
Pflugerville, Texas, United States
Los Angeles, California, United States
Dublin, Ohio, United States
Coral Gables, Florida, United States
Dallas, Texas, United States
Greenwood Village, Colorado, United States
Redondo Beach, California, United States
Santa Rosa, California, United States
West Palm Beach, Florida, United States
Scottsdale, Arizona, United States
Los Angeles, California, United States
San Francisco, California, United States
Westport, Connecticut, United States
Bradenton, Florida, United States
Coral Gables, Florida, United States
Alpharetta, Georgia, United States
Chicago, Illinois, United States
Metairie, Louisiana, United States
Hackensack, New Jersey, United States
Cincinnati, Ohio, United States
Arlington, Virginia, United States
Mequon, Wisconsin, United States
San Juan, , Puerto Rico
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials